Sanofi SA banner

Sanofi SA
PAR:SAN

Watchlist Manager
Sanofi SA Logo
Sanofi SA
PAR:SAN
Watchlist
Price: 78.89 EUR -0.01% Market Closed
Market Cap: €95.6B

EV/FCFF

9.7
Current
34%
Cheaper
vs 3-y average of 14.7

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
9.7
=
Enterprise Value
€105.4B
/
Free Cash Flow to Firm
€10.7B

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
9.7
=
Enterprise Value
€105.4B
/
Free Cash Flow to Firm
€10.7B

Valuation Scenarios

Sanofi SA is trading below its 3-year average

If EV/FCFF returns to its 3-Year Average (14.7), the stock would be worth €118.97 (51% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+63%
Average Upside
51%
Scenario EV/FCFF Value Implied Price Upside/Downside
Current Multiple 9.7 €78.89
0%
3-Year Average 14.7 €118.97
+51%
5-Year Average 15.6 €126.47
+60%
Industry Average 12.8 €103.53
+31%
Country Average 15.8 €128.44
+63%

Forward EV/FCFF
Today’s price vs future free cash flow to firm

Not enough data available to calculate forward EV/FCFF

Peer Comparison

All Multiples
EV/FCFF
P/E
All Countries
Close

Market Distribution

Lower than 74% of companies in France
Percentile
26th
Based on 1 359 companies
26th percentile
9.7
Low
0.9 — 10.4
Typical Range
10.4 — 25.1
High
25.1 —
Distribution Statistics
France
Min 0.9
30th Percentile 10.4
Median 15.8
70th Percentile 25.1
Max 2 752.4

Sanofi SA
Glance View

Sanofi SA, a titan in the global healthcare sector, operates at the intricate crossroads of pharmaceutical innovation and patient care, driven by an unyielding commitment to improving human health. Emerging from its French roots, Sanofi has strategically positioned itself as a global leader in pharmaceuticals, vaccines, and consumer healthcare. The company’s success is essentially anchored in its capacity to consistently develop and commercialize life-saving drugs that address a myriad of health concerns, ranging from diabetes and cardiovascular diseases to rare disorders and oncology. Underlining its robust revenue engine is Sanofi's extensive R&D infrastructure that fuels its pipeline with groundbreaking therapies, reflecting a dynamic blend of scientific acumen and market-focused agility. By leveraging a hybrid model that integrates cutting-edge research with strategic alliances and acquisitions, Sanofi ensures a sustained presence in the highly competitive biopharmaceutical landscape. Enabling this network of innovation and impact is Sanofi's diverse portfolio, a balanced mix of specialty and established prescription drugs, over-the-counter products, and the critical arm of vaccines led by its Sanofi Pasteur division. This diversification offers both growth opportunities and stability, cushioning against the volatile tides of patent expirations and regulatory changes. Its vaccines segment, in particular, is a cornerstone in Sanofi's business, capturing substantial market share with products critical to global immunization efforts, further amplified by its role in responding to health emergencies like the COVID-19 pandemic. With a geographically expansive sales footprint and strategic marketing strategies, Sanofi capitalizes on emerging market opportunities while maintaining a strong presence in established regions, effectively making its bottom line a testimony to its operational excellence and strategic foresight in harmonizing science with humanity.

SAN Intrinsic Value
121.97 EUR
Undervaluation 35%
Intrinsic Value
Price €78.89
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett